CD22 (Epratuzumab Biosimilar) anticorps

N° du produit ABIN7515694

Détail du produit anti-CD22 (Epratuzumab Biosimilar) anticorps

Antigène: CD22 (Epratuzumab Biosimilar)

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp CD22 (Epratuzumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS)

Fonction: Humanized recombinant monoclonal antibody raised against human CD22.

Specificité: This antibody was prepared by the humanization of LL2, a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10 % of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity.

Réactivité croisée: Humain

Immunogène: Original antibody is raised against by the humanization of LL2, a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces

Clone: HL22

Isotype: IgG1

Information d'application

Indications d'application: Flow cytometry,The optimal working dilution should be determined by the end user.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In PBS with 0.02 % Proclin 300.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Détails sur CD22 (Epratuzumab Biosimilar)

Antigène: CD22 (Epratuzumab Biosimilar)

Abstract: CD22 (Epratuzumab Biosimilar) Produits

Synonymes: anticorps SIGLEC-2, anticorps SIGLEC2, anticorps CD22 molecule, anticorps CD22

Classe de substances: Biosimilar

Sujet: CD22 Molecule

ID gène: 933